Ziftomenib
Ziftomenib is an experimental drug for the treatment of cancer. It is being studied for use in patients with relapsed or refractory acute myeloid leukaemia. Ziftomenib blocks the interaction between two proteins, menin (MEN1) and KMT2A (also known as mixed lineage leukemia protein, MLL). This results in an inhibition of the proliferation of leukemic cells. Ziftomenib has been granted breakthrough therapy designation by the Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo .... References {{antineoplastic-drug-stub Antineoplastic and immunomodulating drugs Trifluoroethyl compounds Sulfonamides Indoles Nitriles Thienopyrimidines Piperidines Piperazines Secondary amines ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]